Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches driving advances in heart care. Medtech giants like Medtronic, Abbott, and Edwards Lifesciences captured the minds of MassDevice readers alongside news from tech giant Apple, which entered the spotlight with a landmark FDA approval. The most popular stories of 2024 […]
Abbott
Abbott earns Medicare win for CardioMems
An Abbott official said on social media that the company secured a significant Medicare win for its CardioMEMS platform. Keith Boettiger, VP of Abbott’s heart failure business, posted the update on LinkedIn. He said CMS granted a new national coverage determination for CardioMEMS. “This decision is a massive step forward toward increasing access to CardioMEMS […]
The top medtech stories of 2024
AFib-treating cardiac ablation, surgical robotics, nitinol and diabetes treatment tech lead among this year’s top medtech stories. Meanwhile, medical device companies have been seeking more tuck-in M&A — and continuing to refocus and boost operational efficiency — to better prepare for whatever the future brings. Here are the top medtech stories that caught the attention […]
Abbott, Dexcom settle global CGM patent litigation
Abbott and Dexcom, two leaders in the continuous glucose monitor market, today struck a settlement agreement for ongoing patent litigation. Our sibling site, Drug Delivery Business News, reports today that the companies settled all outstanding patent disputes between them. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. The companies and Dexcom […]
Edwards Lifesciences scores a win at CMS for TTVR
The Centers for Medicare & Medicaid Services (CMS) has announced a proposed decision to cover transcatheter tricuspid valve replacement (TTVR) for Medicare beneficiaries with severe symptomatic tricuspid regurgitation. The proposed decision would allow coverage under a Coverage with Evidence Development (CED) framework, requiring the procedure to be part of a CMS-approved clinical study to ensure […]
Abbott completes first-in-human leadless left bundle branch area pacing procedures
Abbott today announced the successful completion of the world’s first human leadless left bundle branch area pacing (LBBAP) cases. Investigators used the company’s investigational Aveir conduction system pacing (CSP) leadless pacemaker as part of a feasibility study. The procedures mark the first implants of a leadless pacemaker in the left bundle branch area. Abbott says […]
European court rules in favor of Abbott in Dexcom CGM patent spat
Abbott received the backing of the Unified Patent Court in Europe in a CGM infringement battle with Dexcom . Our sister site, Drug Delivery Business News, reports today that the court revoked a patent entirely, dismissing claims of infringement made by Dexcom. The two companies are two leaders in the continuous glucose monitoring (CGM) space. They […]
Medtech M&A could be on the rise in 2025
Analysts from Bank of America predict a favorable environment for mergers and acquisitions in the medtech space in 2025. Travis Steed, Stephanie Piazzola, Craig Bijou and Enjia Cao say 2024 was “a typical year” in terms of M&A in medtech. They tracked 19 acquisitions of note with around $25 billion in disclosed deal price. Some […]
Abbott reports first cases with software-guided balloon-expandable TAVI
Abbott (NYSE:ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) system. The company designed its investigational software-guided, balloon-expandable TAVI system to build a foundation for AI-guided procedures. It hopes to add the expandable system to its structural heart portfolio alongside the already available Navitor TAVI system. Abbott designed its […]
Insulet Omnipod 5 is now compatible with Abbott FreeStyle Libre 2 Plus
Insulet (Nasdaq:PODD) today announced a new integration making Omnipod 5 the most connected tubeless automated insulin delivery system in the U.S. Our sister site, Drug Delivery Business News, reports today that the company paired Omnipod 5 with the Abbott FreeStyle Libre 2 Plus CGM. Compatibility in the U.S. comes about eight months after the company integrated […]
Abbott reports positive Amplatzer Amulet data in head-to-head trial with Boston Scientific’s Watchman
Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system. The company presented data highlighting Amplatzer Amulet’s benefits in treating people with AFib at an increased risk of stroke. According to a news release, new five-year data demonstrates that the technology helps more patients avoid long-term use of blood-thinning medication […]
